000			03605nam a2200313 4500
001			384278
010			_a9291681687
090			_a384278
100			_a20070514d2004 y0pory50 ba
101			_aeng
200			_aHepatitis C and injecting drug use _eimpacts, costs and policy options _fEuropean Monitoring Centre for Drugs and Drug Addiction, EMCDDA
210			_aLuxembourg _cOffice for Official Publications of the European Communities _d2004
215			_a389 p. _d24 cm
225			_aEMCDDA Monographs _v7
300			_aTambém disponível em formato pdf através de: https://www.emcdda.europa.eu/?nnodeid=428
330			_aForeword (Georges Estievenart). General introduction (Wien Limburg; Lucas Wiessing; Johannes Jager). Part I - Natural history, treatment, quality of life, epidemiology and prevention: introduction. Chapter 1 - Natural history, treatment and prevention of hepatitis C in injecting drug users: an overview (Wien Limburg). Chapter 2 - Recent developments in hepatitis C diagnostics and treatment (Thierry Poynard). Chapter 3 - Hepatitis C and quality of life (Graham Foster). Chapter 4 - Surveillance of hepatitis C infection among injecting drug users in the European Union (Lucas Wiessing; Kirsty Roy; David Sapinho; Gordon Hay; Avril Taylor; David Goldberg; Richard Hartnoll). Part II - Models of hepatitis C, injecting drug use and policy options: Introduction. Chapter 5 - Modelling the transmission of hepatitis C in injecting drug users (Mirjam Kretzschmar; Lucas Wiessing). Chapter 6 - Modelling injecting drug use and hepatitis C in injecting drug users (Carla Rossi; Nicolina Esposito). Chapter 7 - Modelling policy options to control problem drug use (Gernot Tragler). Part III - Healthcare costs of drug-related hepatitis C infection: introduction. Chapter 8 - Updated healthcare cost estimates for drug-related hepatitis C infections in the European Union (Maarten Postma; Lucas Wiessing and Johannes Jager). Chapter 9 - Cost-effectiveness of treatment of hepatitis C in injecting drug users (John Wong; Diana Sylvestre; Uwe Siebert). Part IV - Wider costs of drug use: introduction. Chapter 10 - Assessment of the indirect costs of injecting drug use: which methods should be employed? (Robert Welte; Hans-Helmut König; Johannes Jager; Reiner Leidl). Chapter 11 - Models to compute the costs to society of injecting drug use and related morbidity (Fernando Antoñanzas; Roberto Rodríguez; María Velasco). Chapter 12 - Assessing the tangible and intangible costs of illicit drug use. Chapter 13 - Social costs of drug use in France (Pierre Kopp; Nicolas Blanchard). Part V - Cost-effectiveness of needle and syringe programmes and methadone maintenance: introduction. Chapter 14 - Cost-effectiveness of needle and syringe programmes: a review of the literature (Ardine de Wit; Jasper Bos). Chapter 15 - The impact and cost-effectiveness of methadone maintenance treatment in preventing HIV and hepatitis C (Harold Pollack; Robert Heimer). General conclusions (Lucas Wiessing; Wien Limburg; Johannes Jager). Contributors. Abbreviations.
606			_aPREVENÇÃO DA TOXICODEPENDÊNCIA _9103892
606			_aDOENÇA INFECCIOSA _9100267
606			_aPOLÍTICA DE SAÚDE _9234372
606			_aPOLÍTICA SOCIAL _9234807
606			_aPOLÍTICA ORÇAMENTAL _9235030
606			_aOEDT _9321506
606			_aUNIÃO EUROPEIA _9224774
710			_aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION _9351987
955			_xOferta